NO983456D0 - Rekombinante fager - Google Patents

Rekombinante fager

Info

Publication number
NO983456D0
NO983456D0 NO983456A NO983456A NO983456D0 NO 983456 D0 NO983456 D0 NO 983456D0 NO 983456 A NO983456 A NO 983456A NO 983456 A NO983456 A NO 983456A NO 983456 D0 NO983456 D0 NO 983456D0
Authority
NO
Norway
Prior art keywords
bacteriophages
bacterial
component
infections
relates
Prior art date
Application number
NO983456A
Other languages
English (en)
Other versions
NO983456L (no
NO323359B1 (no
Inventor
Sven Mordh
Original Assignee
Phagen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phagen Ab filed Critical Phagen Ab
Publication of NO983456D0 publication Critical patent/NO983456D0/no
Publication of NO983456L publication Critical patent/NO983456L/no
Publication of NO323359B1 publication Critical patent/NO323359B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14111Inoviridae
    • C12N2795/14132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19983456A 1996-02-06 1998-07-27 Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. NO323359B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600434A SE506771C2 (sv) 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
PCT/SE1997/000172 WO1997029185A1 (en) 1996-02-06 1997-02-05 Recombinant phages

Publications (3)

Publication Number Publication Date
NO983456D0 true NO983456D0 (no) 1998-07-27
NO983456L NO983456L (no) 1998-10-06
NO323359B1 NO323359B1 (no) 2007-04-10

Family

ID=20401289

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983456A NO323359B1 (no) 1996-02-06 1998-07-27 Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel.

Country Status (16)

Country Link
EP (1) EP0889955B1 (no)
JP (1) JP4015195B2 (no)
KR (1) KR100459638B1 (no)
CN (1) CN1125174C (no)
AT (1) ATE266091T1 (no)
AU (1) AU712767B2 (no)
CA (1) CA2244792A1 (no)
DE (1) DE69728975T2 (no)
ES (1) ES2221033T3 (no)
HU (1) HUP9901242A3 (no)
IL (2) IL125645A0 (no)
NO (1) NO323359B1 (no)
NZ (1) NZ331580A (no)
RU (1) RU2215032C2 (no)
SE (1) SE506771C2 (no)
WO (1) WO1997029185A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100890A2 (en) 1998-07-27 2001-05-23 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
GB9908195D0 (en) * 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
ES2242620T3 (es) 1999-06-14 2005-11-16 Genentech, Inc. Estructuras peptidicas para exhibir bibliotecas de giros de un fago.
EP1305038B1 (en) * 2000-07-25 2005-10-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Bacteriophage having multiple host range
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
KR20040036176A (ko) * 2002-10-23 2004-04-30 (주)엘피스바이오텍 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법
CN102296051B (zh) * 2011-03-07 2014-09-17 江苏省农业科学院 一种宽宿主谱鸡白痢沙门氏菌噬菌体及其应用
RU2503716C1 (ru) * 2012-09-27 2014-01-10 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) ВИДОСПЕЦИФИЧЕСКИЙ ВИРУЛЕНТНЫЙ ШТАММ БАКТЕРИОФАГА, ОБЛАДАЮЩИЙ ЛИТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ Staphylococcus aureus, ВКЛЮЧАЯ МУЛЬТИРЕЗИСТЕНТНЫЕ ШТАММЫ
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN106198523A (zh) * 2016-07-06 2016-12-07 哈尔滨贝贝凯尔科技发展有限公司 微量元素检测试纸及其制备方法
CA3078460A1 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
EP3909644A4 (en) * 2018-12-27 2022-10-05 National University Corporation Tokai National Higher Education and Research System NANOPARTICLE SPECIFIC TO A HOST BACTERIA
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
SE9304060D0 (sv) * 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager

Also Published As

Publication number Publication date
CN1125174C (zh) 2003-10-22
AU1681797A (en) 1997-08-28
IL125645A (en) 2006-08-20
IL125645A0 (en) 1999-04-11
NZ331580A (en) 1999-09-29
AU712767B2 (en) 1999-11-18
RU2215032C2 (ru) 2003-10-27
KR100459638B1 (ko) 2005-02-24
JP2000505648A (ja) 2000-05-16
NO983456L (no) 1998-10-06
CN1210558A (zh) 1999-03-10
EP0889955B1 (en) 2004-05-06
DE69728975D1 (de) 2004-06-09
ES2221033T3 (es) 2004-12-16
CA2244792A1 (en) 1997-08-14
SE506771C2 (sv) 1998-02-09
EP0889955A1 (en) 1999-01-13
DE69728975T2 (de) 2005-05-04
NO323359B1 (no) 2007-04-10
SE9600434L (sv) 1997-08-07
WO1997029185A1 (en) 1997-08-14
HUP9901242A2 (hu) 1999-07-28
JP4015195B2 (ja) 2007-11-28
ATE266091T1 (de) 2004-05-15
HUP9901242A3 (en) 2000-03-28
KR19990082041A (ko) 1999-11-15
SE9600434D0 (sv) 1996-02-06

Similar Documents

Publication Publication Date Title
NO983456D0 (no) Rekombinante fager
DK0587780T4 (da) Smitstof, som forårsager Mystery Swine Disease,vaccinepræparater og diagnostiske sæt
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
DE69940404D1 (de) Multikomponenten Impfstoffe gegen Staphylococcus aureus
DE60113851D1 (de) Bakteriophage mit breitem wirtspektrum
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
RS54133B1 (en) ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
TR200002437T2 (tr) B grubu streptococcus antijenleri.
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
DE69938935D1 (de) Zyklische conotoxin-peptide
AR016295A1 (es) Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
DE69737323D1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
NO985412D0 (no) Type-2 kjemokinbindende proteiner og anvendelser derav
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
ATE385805T1 (de) Neue peptide
ATE435034T1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.